Potential of the natural products against leishmaniasis in Old World - a review of in-vitro studies

Pathog Glob Health. 2020 May 18;114(4):170-182. doi: 10.1080/20477724.2020.1754655. Epub 2020 Apr 27.

Abstract

Leishmaniasis is a vector-borne disease among the 10 most Neglected Tropical Diseases with diverse clinical manifestations caused by protozoan parasites of the Leishmania genus. Around 80% of leishmaniasis cases are found in the Old World affecting populations mainly in low and middle-income countries. Its control relies mostly on chemotherapy which still presents many drawbacks. Natural products may offer an inexhaustible source of chemical diversity with therapeutic potential. Despite the lack of knowledge on traditional products with activity against Leishmania parasites, many reports describe the search for natural extracts and compounds with antileishmanial properties against promastigote and amastigote parasite forms. This review summarizes the research of 74 publications of the last decade (2008-2018) focused on the identification of endemic plant-derived products that are active against Old World Leishmania parasites responsible for cutaneous and visceral leishmaniasis. The present review combines data on antileishmanial activity of 423 plants species, belonging to 94 different families, including a large range of crude extracts which lead to the isolation of 86 active compounds. Most studied plants came from Asia and most promising plant families for antileishmanial activity were Asteraceae and Lamiaceae. From the chemical point of view, terpenoids were the most frequently isolated natural products. These studies suggest that natural products isolated from Old World flora are a rich source of new chemical scaffolds for future leishmaniasis treatment as well as for other Neglected Tropical Diseases warranting further investigation.

Keywords: Leishmaniasis; Old World Leishmania spp; antileishmanial activity; natural compounds; plants.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiprotozoal Agents* / therapeutic use
  • Asia
  • Biological Products* / therapeutic use
  • Chlorocebus aethiops
  • Leishmaniasis* / drug therapy
  • Plant Extracts* / therapeutic use
  • Vero Cells

Substances

  • Antiprotozoal Agents
  • Biological Products
  • Plant Extracts

Grants and funding

This work was supported by the Fundação para a Ciência e a Tecnologia [UID/Multi/04413/2013 (GHTM)]; Fundação para a Ciência e a Tecnologia [SFRH/BD/78062/2011]; Fundação para a Ciência e a Tecnologia [IF/00743/2015]; CAPES [001]; CNPq [301357/2019-7]; FAPESP [18/07585-1].